Oraya Therapeutics Publishes Results of Wet AMD Treatment Study

Oraya Therapeutics, Newark, Calif.-based minimally invasive ophthalmic treatment company, has published the results of a study analyzing the effectiveness and safety of its wet age-related macular degeneration therapy in Ophthalmology.

Advertisement

The INTREPID study demonstrated that Oraya Therapy Stereotactic Radiotherapy decreased the amount of anti-VEGF injections needed to treat macular degeneration patients.

More Articles on Ophthalmology:
3 Statistics on Cataract Surgery Procedure Times in ASCs
Abbott Medical Optics Appoints Dr. David Tanzer Chief Medical Officer
Hubble Telemedical Launches EyeQ Wellness Exam

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.